Skip to main content

CORRECTION article

Front. Oncol., 25 August 2023
Sec. Pharmacology of Anti-Cancer Drugs
Volume 13 - 2023 | https://doi.org/10.3389/fonc.2023.1275851

Corrigendum: Correlation analysis of MRD positivity in patients with completely resected stage I-IIIA non-small cell lung cancer: a cohort study

This article is a correction to:

  1. Correlation analysis of MRD positivity in patients with completely resected stage I-IIIA non-small cell lung cancer: a cohort study

    1. Read original article
Daling Dong&#x;Daling Dong1†Shixin Zhang&#x;Shixin Zhang1†Bin JiangBin Jiang1Wei WeiWei Wei1Chao WangChao Wang1Qian YangQian Yang1Tingzhi YanTingzhi Yan1Min ChenMin Chen1Liken ZhengLiken Zheng2Weikang ShaoWeikang Shao2Gang Xiong*Gang Xiong1*
  • 1Department of Cardiothoracic Surgery, Guiqian International Hospital, Guiyang, China
  • 2Genecast Biotechnology Co., Ltd., Wuxi, China

A Corrigendum on
Correlation analysis of MRD positivity in patients with completely resected stage I-IIIA non-small cell lung cancer: a cohort study

by Dong D, Zhang S, Jiang B, Wei W, Wang C, Yang Q, Yan T, Chen M, Zheng L, Shao W and Xiong G (2023) Front. Oncol. 13:1222716. doi: 10.3389/fonc.2023.1222716

In the published article, there was an error regarding the affiliation for the author Gang Xiong. Instead of Gang Xiong1,2*, it should be Gang Xiong1*.

In addition, there was an error in Supplementary Data Sheet 1.zip (Table 3). The Supplementary material contains sensitive information about the patient that has not been deleted, and some of the descriptions in the table have not been converted to English, which will affect the reader’s reading experience. The correct supplementary material statement appears below.

Table 3 Patient baseline information and MRD status

The authors apologize for these errors and state that these do not change the scientific conclusions of the article in any way. The original article has been updated.

Publisher’s note

All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article, or claim that may be made by its manufacturer, is not guaranteed or endorsed by the publisher.

Keywords: molecular residual disease, liquid biopsy, non-small cell lung cancer, adjuvant therapy, clinicopathological features, immune markers

Citation: Dong D, Zhang S, Jiang B, Wei W, Wang C, Yang Q, Yan T, Chen M, Zheng L, Shao W and Xiong G (2023) Corrigendum: Correlation analysis of MRD positivity in patients with completely resected stage I-IIIA non-small cell lung cancer: a cohort study. Front. Oncol. 13:1275851. doi: 10.3389/fonc.2023.1275851

Received: 10 August 2023; Accepted: 15 August 2023;
Published: 25 August 2023.

Edited and Reviewed by:

Lin Qi, Central South University, China

Copyright © 2023 Dong, Zhang, Jiang, Wei, Wang, Yang, Yan, Chen, Zheng, Shao and Xiong. This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.

*Correspondence: Gang Xiong, xionggang_xw@sina.com

†These authors have contributed equally to this work

Disclaimer: All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article or claim that may be made by its manufacturer is not guaranteed or endorsed by the publisher.